[New Publication] Tumor-on-a-Chip Guided NSCLC Nanotherapy

Our latest research has been published in Chemical Engineering Journal:

Title: Nanoengineered Redox-Responsive Platforms for Dual-Targeted NSCLC Therapy with Tumor-on-a-Chip Epithelial-Mesenchymal Transition Profiling

In this work, we present a rationally designed binary hybrid nanoassembly (OL@R NPs) that co-delivers a redox-responsive platinum(IV) prodrug of oxaliplatin and the ferroptosis inducer RSL3. This nanoplatform:

1. Triggers tumor-selective drug release via elevated intracellular glutathione (GSH) levels.
2. Induces dual cell death mechanisms (apoptosis + ferroptosis) to overcome epithelial-mesenchymal transition (EMT)-associated drug resistance.
3. Demonstrates strong efficacy in both an advanced tumor microenvironment-on-a-chip (TMEOC) model and NSCLC-bearing mice, suppressing tumor growth while reducing off-target toxicity.

By combining chemotherapy and ferroptosis in a single nanosystem, this study highlights a promising therapeutic approach to tackle chemoresistant non-small cell lung cancer (NSCLC) and paves the way for safer, more effective treatments.

Authors: Wenjing Ma, Haowen Tian, Jianbin Shi, Jia Deng, Naiyuan Hu, Wenqian Xu, Ayumi Kikkawa, Kaho Tanaka, Cuo Luo, Ken-ichiro Kamei*, and Chutong Tian*